News and Events San Diego, CA February 21st, 20011 - Avineuro Pharmaceuticals, Inc. reported today positive top-line results from a Phase 2a clinical proof of concept trial to assess AVN-211 as an augmentation therapy to improve cognition in schizophrenia patients. In a double blind trial in 50 ...

News and Events Avineuro Pharmaceuticals, Inc. participates in BioNetwork West 2009 conference in Laguna Niguel, CA on October 5-7, 2009 BioNetwork offers the opportunity to meet with VPs of Business Development, Licensing, and Aliance Management from top companies offering their insights. Most impo...

News and Events 11.02.2009 11.04.2009 Avineuro Pharmaceuticals, Inc. participates in ABIO-Europe 2009 conference in Vienna on November 2-4, 2009 BIO-Europe is Europes largest partnering conference, serving the global biotechnology industry. The conference annually attracts leading dealmakers from bi...

News and Events Archive for the News Category Older Entries Avineuro Pharmaceuticals, Inc. reports positive Phase 2a clinical proof of concept trial results on AVN-211, potent small molecule for treatment of schizophrenia. Monday, February 21st, 2011 San Diego, CA February 21st, 20011 - Avineuro...

News and Events 03.08.2010 03.10.2010 Avineuro Pharmaceuticals, Inc. will be presenting at ABIO-Europe 2010 conference in Barcelona, Spain on Wednesday, March 10th at 10.45 am BIO-Europe Spring is the springtime counterpart to EBD Group s flagship conference, BIO-Europe, and continues the traditio...